NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, announced that its Board of Directors has authorized a share repurchase program of up to $2.0 million of the Company’s common stock over the next 18 months.
